Tag: GLP-1 analogue

Novo’s oral semaglutide beats Lilly/Boehringer’s Jardiance

by Selina McKee | May 30, 2018 | News | 0

Novo Nordisk has announced headline data from the PIONEER 2 trial showing that oral semaglutide was better at improving HbA1c levels in patients with type II diabetes than Lilly’s and Boehringer Ingelheim’s Jardiance.

Novo files once-weekly GLP-1 analogue semaglutide

by Selina McKee | Dec 6, 2016 | News | 0

Novo Nordisk has filed its once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide with regulators on both sides of the Atlantic, seeking permission to market the drug for the treatment of adults with type II diabetes.